Musculoskeletal Citations

Chronic Fatigue Syndrome: A Review of the Evidence

June 22, 2015

Difficult diagnosis, overlap with other conditions, lack of objective signs, the absence of proven treatment. . . these reviews of chronic fatigue syndrome filter and summarize the most rigorous evidence available.

Drugs for Psoriatic Arthritis--and Their Cost

June 22, 2015

This overview of NSAIDs, corticosteroids, DMRDs, PDE4 inhibitors, and biologic agents offers recommendations for first-line options for mild and moderate-to-severe psoriatic arthritis.

Tofacitinib in Chronic Plaque Psoriasis

June 17, 2015

In a 12-week phase 3 trial, tofacitinib,10 mg twice a day, was non-inferior to etanercept, 50 mg twice a week. Tofacitinib, 5 mg twice a day, was inferior to etanercept.

Your History of Viral Exposure Revealed

June 16, 2015

The VirScan system can measure a subject's exposure to all known human viruses. This will enable population studies that find any associations with a particular viral infection for every rheumatological disease. And it only costs about $25 per blood sample.

Spondylitis and Aortic Regurgitation

June 12, 2015

Many patients with ankylosing spondylitis have aortic regurgitation: this study makes the case for routine echocardiography evaluation.

NEJM Makes Myositis as Clear as Possible

June 11, 2015

A comprehensive review has compiled and summarized all current information about pathology, diagnosis, and treatment of the various subsets of myositis.

Dental Issues (Not Opening Wide ... ) a Severity Indicator in SSc

June 05, 2015

Hardening of the skin in systemic sclerosis impairs patients' ability to care for their own teeth properly. As a result, this study suggests, dental issues may be prognostic indicators.

Ten Diagnostic Signs of ILD, and More

May 28, 2015

Key features in the clinical examination of interstitial lung diseases and their management are the focus of a new clinical review. Highlights here.

Study Finds Ethnic Pattern in Infliximab Antibody Risk

May 22, 2015

One very targeted clue to treatment failure: An observational study from Israel identifies Sephardic Jews as more likely than Ashkenazim to form antibodies against the biologic drug infliximab.

Adalimumab Safe and Effective for Non-Psoriatic SpA

May 20, 2015

The biologic adalimumab improves pain and physical function in a randomized trial of patients with peripheral spondyloarthritis unable to take non-steroidal anti-inflammatory drugs.